What the FDA labels say about taking them together
Colestipol and maralixibat
Maralixibat's FDA label of April 10, 2025 names colestipol in its drug interactions section; the colestipol labels PlainMeds reads (3) do not name maralixibat.
Check it at the source: the colestipol FDA label on DailyMed (effective February 19, 2024, Zydus Pharmaceuticals USA Inc.); the maralixibat FDA label on DailyMed (effective April 10, 2025, Mirum Pharmaceuticals Inc.).
What does the colestipol label say about maralixibat?
Colestipol's label (effective February 19, 2024) and its 2 other brand-application labels do not name maralixibat in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Colestipol hydrochloride), Zydus Pharmaceuticals USA Inc., effective February 19, 2024 (SPL set 71f12e0d-373a-4867-b37c-f24d99c5ce95), via openFDA; the full label on DailyMed
What does the maralixibat label say about colestipol?
Maralixibat label, drug interactionsAdminister LIVMARLI at least 4 hours before or 4 hours after administration of bile acid binding resins (e.g., cholestyramine, colesevelam, or colestipol).
Source: FDA drug label (Livmarli), Mirum Pharmaceuticals Inc., effective April 10, 2025 (SPL set 64000394-1ef6-4e76-8ba8-11f25ba1b167), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Colestipol | Maralixibat | |
|---|---|---|
| Labeled for | High cholesterol | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.658 per tablet 1 g tablet | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once